SCHEDULE: Deep Track Capital Discloses 5.6% Stake in Tarsus Pharmaceuticals

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.6% in Tarsus Pharmaceuticals, Inc.'s common stock.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 2,352,960 shares of Tarsus Pharmaceuticals, Inc. common stock.
• This ownership represents 5.60% of the outstanding common stock of Tarsus Pharmaceuticals, Inc.
• The calculation of the percentage is based on 42,014,237 common shares outstanding as of April 24, 2025, as reported in the issuer's 10-Q filed on May 1, 2025.
• The reporting persons share both voting and dispositive power over all 2,352,960 shares.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant ownership stake by an institutional investor. While not directly impacting the company's operations, a new 5%+ holder can be viewed as a positive signal of investor confidence, hence a slightly positive score.

Positives

• A significant stake by an institutional investor like Deep Track Capital may signal confidence in Tarsus Pharmaceuticals' future prospects.

Negatives

• The filing itself, being a beneficial ownership report, does not inherently contain negative financial or operational information about the issuer.

Risks

• The filing does not detail specific risks related to Tarsus Pharmaceuticals, Inc.'s operations or financial health; it is a disclosure of ownership.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Tarsus Pharmaceuticals, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

The disclosure of a significant stake by Deep Track Capital, an investment firm specializing in biotechnology, suggests continued investor interest in the pharmaceutical and biotechnology sectors. Such filings are common as institutional investors accumulate positions in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a new significant shareholder provides transparency regarding the company's ownership structure and may influence market perception and trading activity.

Key Dates

Keywords

Tarsus Pharmaceuticals, Deep Track Capital, Beneficial Ownership, Schedule 13G, Institutional Investor, Biotechnology, Common Stock, Equity Stake